Table 2.
Highest trans-complementation-mediated enhancement of GFP expression of day 2 experiment
| Virus | WtAd5 | AdΔEP-TETP | AdCMV-lacZ | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cell line | MFI expression AdCMV-eGFP MOI 0.37 | Highest fold enhancement | Input MOI AdCMV- eGFP of highest fold enhancement | Ratio WtAd5/AdCMV-eGFP | Highest fold enhancement | Input MOI AdCMV- eGFP of highest fold enhancement |
Ratio AdΔEP-TETP/AdCMV-eGFP |
Highest fold enhancement | Input MOI AdCMV- eGFP of highest fold enhancement |
Ratio AdCMV-lacZ/AdCMV-eGFP |
| HeLa (cervical carcinoma) | 9.0 | 7.2 | 0.37 | 81 | 2.8 | 1.1 | 81 | 1.2 | 1.1/3.3 | 81/9 |
| SW480 (colon carcinoma) | 2.9 | 133 | 0.37 | 243 | 18.3 | 1.1 | 81 | 1.1 | 3.3 | 9 |
| A549 (lung carcinoma) | 7.4 | 25.1 | 3.3 | 3 | 6.9 | 1.1 | 81 | nd | ||
| DLD-1 (colon carcinoma) | 15 | 7.7 | 3.3 | 9 | 3.8 | 0.37 | 243 | nd | ||
| M000301 (melanoma) | 3.3 | 19.1 | 1.1 | 81 | 28.8 | 0.37 | 243 | 3.3 | 0.37 | 243 |
| M21L4 (melanoma) | 3.3 | 11.2 | 0.37 | 243 | 13 | 1.1 | 81 | 1.5 | 1.1 | 27 |
| SK-Mel23 (melanoma) | 1.62 | 6.4 | 3.3 | 27 | 15.4 | 1.1 | 27 | nd | ||
| MeWo (melanoma) | 54 | 3.1 | 0.37 | 243 | 3.5 | 1.1 | 27 | nd | ||
Nd: not determined